Clinical Trial: The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06851299) titled 'The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.' on Feb. 11.

Brief Summary: This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Metastatic Triple-negative Breast Cancer

Intervention: DRUG: trop2-ADC

Accept ADC monotherapy

DRUG: ADC +anti-angiogenic drug

Accept ADC combined...